Patent Panic Gives Green Light to Deals (Financial Times)
The recent announcement of pharma’s latest mega-merger has not been received well by many people, except perhaps Allergan Shareholders. The deal has been highlighted as another defensive mega-merger to protect against patent expiry. In light of this the Financial Times asked John Rountree for his views on the deal: “Continuing to boost top-line growth when […]